Jack Schuler Purchases 15,000 Shares of Biodesix (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 15,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $24.47 per share, for a total transaction of $367,050.00. Following the purchase, the director directly owned 555,810 shares in the company, valued at approximately $13,600,670.70. This represents a 2.77% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Biodesix Stock Down 1.8%

BDSX traded down $0.43 during trading on Thursday, reaching $23.79. The stock had a trading volume of 49,855 shares, compared to its average volume of 626,441. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 5.12. The company has a market capitalization of $250.98 million, a price-to-earnings ratio of -7.50 and a beta of 0.56. The stock’s 50 day moving average is $20.19 and its two-hundred day moving average is $16.05. Biodesix, Inc. has a one year low of $5.26 and a one year high of $25.52.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The company had revenue of $26.86 million during the quarter, compared to analyst estimates of $26.03 million. As a group, analysts expect that Biodesix, Inc. will post -2.68 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on BDSX. HC Wainwright restated a “buy” rating and set a $27.00 price objective (up from $26.00) on shares of Biodesix in a research note on Thursday, August 6th. Canaccord Genuity Group increased their price target on shares of Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Finally, Roth Capital initiated coverage on shares of Biodesix in a report on Wednesday, June 24th. They issued a “buy” rating and a $32.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.33.

Institutional Trading of Biodesix

A number of hedge funds have recently bought and sold shares of BDSX. Cetera Investment Advisers increased its position in Biodesix by 20.0% in the first quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock worth $174,000 after buying an additional 2,000 shares in the last quarter. Geode Capital Management LLC raised its stake in Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares during the period. State Street Corp lifted its holdings in Biodesix by 15.6% during the fourth quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after purchasing an additional 2,400 shares in the last quarter. Allworth Financial LP bought a new position in shares of Biodesix in the second quarter worth approximately $112,000. Finally, Walleye Capital LLC purchased a new stake in shares of Biodesix in the first quarter worth $157,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.